Welcome to our dedicated page for Ionis Pharmaceuticals SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, along with AI-powered summaries to help interpret complex documents. As a biotechnology issuer focused on RNA-targeted medicines, Ionis uses filings such as Forms 8-K, 10-Q and 10-K to report clinical milestones, regulatory events, financing transactions and operating results.
Recent Form 8-K filings illustrate how Ionis communicates material developments. The company has furnished press releases on pivotal Phase 3 CORE and CORE2 results for olezarsen in severe hypertriglyceridemia, positive pivotal data for zilganersen in Alexander disease, and FDA approval of DAWNZERA (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema. Other 8-Ks describe FDA Breakthrough Therapy designations, European regulatory opinions and key clinical readouts across neurology and cardiometabolic programs.
Ionis also uses current reports to disclose capital markets activity. One 8-K details the issuance of 0.00% Convertible Senior Notes due 2030, including the terms of the indenture, conversion mechanics, redemption provisions, events of default and use of proceeds, such as repurchasing earlier convertible notes and funding general corporate purposes. Additional filings cover quarterly financial results, where the company presents both GAAP and non-GAAP measures, and governance or contractual matters like advisory services agreements.
On this page, Stock Titan connects directly to EDGAR to surface new Ionis filings as they are posted. AI-powered summaries help explain lengthy documents, highlighting items such as clinical trial outcomes, regulatory status updates, financing terms, risk factor changes and other key disclosures. Investors can quickly locate annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and other relevant filings, and use the AI analysis to understand how each document may relate to Ionis’ RNA-targeted pipeline, marketed medicines and capital structure.
Ionis Pharmaceuticals director Joseph Klein III exercised stock options and sold shares on April 1, 2026. He exercised options for 12,000 shares at $38.06 and 10,321 shares at $41.08, acquiring a total of 22,321 common shares. He then sold 20,105 shares at a weighted average price of $75.503 and 2,216 shares at $75.954 in open-market transactions pursuant to a Rule 10b5-1 Trading Plan adopted on November 26, 2025. After these transactions, he held 11,014 shares directly. An additional 100 shares are held indirectly by his son, for which he disclaims beneficial ownership.
Ionis Pharmaceuticals executive Shannon L. Devers, EVP and Chief Human Resources Officer, sold 6,193 shares of Common Stock in an open-market transaction at a weighted average price of $74.0535 per share on April 2, 2026. The sale was made pursuant to a Rule 10b5-1 Trading Plan adopted on November 24, 2025. After this transaction, Devers directly holds 16,348 shares of Ionis Pharmaceuticals common stock.
IONS notice of proposed sale of 68,800 shares of Common Stock under Rule 144. The form lists a sale venue as Nasdaq and an effective/filing date of 03/03/2026. The excerpt also shows 50,432 shares from an option exercise and 18,368 RSUs with grant dates.
Ionis Pharmaceuticals Inc: The Vanguard Group filed Amendment No. 14 to a Schedule 13G/A reporting beneficial ownership in Ionis Pharmaceuticals common stock. The filing states 0 shares beneficially owned and 0% of the class, after an internal realignment of Vanguard subsidiaries.
The filing explains that on January 12, 2026 Vanguard reorganized certain subsidiaries to report separately in reliance on SEC Release No. 34-39538; the reporting entity now states no beneficial ownership in the class. The form is signed by Ashley Grim, Head of Global Fund Administration.
IONS filing amends a Form 144 reporting proposed sales of Common Stock by a selling holder. The filing lists sales dated 01/16/2026 and 01/30/2026 with reported quantities of 9,302 and 6,179 respectively. The securities are listed as Common Stock on Nasdaq.
Ionis Pharmaceuticals executive Eugene Schneider reported an open-market sale of 5,812 shares of Common Stock. The shares were sold at a weighted average price of $70.9715 per share on March 19, 2026, under a pre-arranged Rule 10b5-1 trading plan. After the transaction, Schneider directly holds 63,890 shares.
IONS affiliate filed a Form 144 to sell Common Stock. The notice lists proposed sales tied to 01/15/2026 performance stock units and a reported sale on 03/19/2026. The filing names Stifel Nicolaus & Company as broker and lists quantities including 6179 shares sold in the past three months and figure 512906.00.
Ionis Pharmaceuticals EVP, Finance & CFO Elizabeth L. Hougen reported a series of stock option exercises followed by open-market sales of common stock. On March 16, 2026, she exercised options to acquire a total of 174,999 shares of common stock at exercise prices of $32.6000, $37.5800, $56.7800 and $60.8900 per share. That same day, she sold 215,048 shares of common stock in open-market transactions at weighted average prices of $72.3810 and $72.7650 per share. On March 17, 2026, she sold an additional 10,172 shares at a weighted average price of $73.2070 per share, bringing total reported sales to 225,220 shares. The filing states these sales were made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2025. Following the transactions, Hougen directly owns 82,660 shares of Ionis common stock.
IONS notice of proposed resale of 225,200 shares of Common Stock. The form lists 225,200 shares to be sold pursuant to an option exercise with cash proceeds and identifies Stifel Nicolaus & Company Inc as a broker. The filing also records two prior dispositions by Elizabeth Hougen of 6,988 and 12,922 shares on 01/30/2026 and 01/16/2026, respectively, with their cash amounts.
Ionis Pharmaceuticals executive Patrick R. O'Neil reported an open-market sale of 10,148 shares of common stock at an average price of $75.2525 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025.
Following this sale, O'Neil directly holds 62,211 Ionis shares. The reported sale price reflects a weighted average, with individual trades completed between $74.98 and $75.51 per share.